IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for IRIX
-0.16 (-1.47%)
Feb 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.16 - 10.90
52 week 6.41 - 11.01
Open 10.61
Vol / Avg. 34,573.00/19,415.00
Mkt cap 104.58M
P/E 64.64
Div/yield     -
EPS 0.17
Shares 9.84M
Beta 1.29
Inst. own 54%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.84% 5.83%
Operating margin 5.99% 6.88%
EBITD margin - 6.92%
Return on average assets 6.06% 7.13%
Return on average equity 7.66% 9.34%
Employees 101 -
CDP Score - -


1212 Terra Bella Ave
MOUNTAIN VIEW, CA 94043-1824
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The main focus of the Company is on ophthalmology business. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases. The Company�s ophthalmology business includes repair, servicing and extended service contracts for its laser systems, and a capital component, consisting of the laser consoles combined with durable delivery devices (laser systems). Its laser consoles consist of IQ products, which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems and OcuLight products including OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems.

Officers and directors

Will M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
James H. Mackaness Chief Financial Officer, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Ronald T. Steckel Vice President - Operations
Bio & Compensation  - Reuters
George R Marcellino PhD Director
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 47
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 73
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters